T1	Participants 340 470	Forty-nine patients (40 with abnormal cell-mediated immunity) participated in a randomized, double-blind, placebo-controlled trial
T2	Participants 564 572	patients
T3	Participants 1361 1386	immunoglobulin recipients
T4	Participants 1413 1431	placebo recipients
